@article{a0e951d064b24a148b4aa245fd756e0e,
title = "Taking T-Cell Oncotherapy Off-the-Shelf",
abstract = "Banked allogeneic or {\textquoteleft}off-the-shelf{\textquoteright} (OTS) T cells from healthy human donors are being developed to address the limitations of autologous cell therapies. Potential challenges of OTS T cell therapies are associated with their allogeneic origin and the possibility of graft-versus-host disease (GvHD) and host-versus-graft immune reactions. While the risk of GvHD from OTS T cells has been proved to be manageable in clinical studies, approaches to prevent immune rejection of OTS cells are at an earlier stage of development. We provide an overview of strategies to generate OTS cell therapies and mitigate alloreactivity-associated adverse events, with a focus on recent advances for preventing immune rejection.",
keywords = "Allogeneic banked cells, Immune effectors",
author = "Feiyan Mo and Maksim Mamonkin and Brenner, {Malcolm K.} and Heslop, {Helen E.}",
note = "Funding Information: The authors thank Catherine Gillespie for editing the manuscript. This project was supported by the National Cancer Institute (F99CA253757, P50CA126752, and P01CA094237), the SU2C/AACR 604817 Meg Vosburg T Cell Lymphoma Dream Team, and the Leukemia and Lymphoma Society. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. H.E.H. is a cofounder with equity in Allovir and Marker Therapeutics; serves on advisory boards for Gilead Sciences, Tessa Therapeutics, Novartis, PACT Pharma, and Kiadis; and has received research funding from Tessa Therapeutics and Kuur Therapeutics. M.K.B. is a cofounder with equity in Allovir, Marker Therapeutics, and Tessa Therapeutics and serves on advisory boards for Tessa Therapeutics, Allogene, Memgen, Kuur Therapeutics, Walking Fish Therapeutics, Tscan, Abintus, and Turnstone Biologics. M.M. F.M. and M.K.B. are coinventors on a patent related to ADRs and methods of their use that is licensed to Fate Therapeutics and Allogene Therapeutics. Funding Information: The authors thank Catherine Gillespie for editing the manuscript. This project was supported by the National Cancer Institute ( F99CA253757 , P50CA126752 , and P01CA094237 ), the SU2C/AACR 604817 Meg Vosburg T Cell Lymphoma Dream Team , and the Leukemia and Lymphoma Society . Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",
year = "2021",
month = mar,
doi = "10.1016/j.it.2021.01.004",
language = "English (US)",
volume = "42",
pages = "261--272",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Ltd",
number = "3",
}